Background: The abnormal biological activity of cytokines plays an important role in the pathophysiology of both systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). Several studies have highlighted the association of vitamin D and certain proinflammatory cytokines with disease activity in SLE. However, there are limited data on the association of vitamin D and antiphospholipid antibodies (aPL) with various proinflammatory biomarkers in these patients and their relative impact on clinical outcomes. Methods: The serum levels of several aPL, 25-hydroxy-vitamin D, pro-inflammatory cytokines including IFNa, IL-1b, IL-6, IL-8, IP10, sCD40L, TNFa and VEGF were measured in 312 SLE patients from the Jamaican (n ¼ 45) and Hopkins (n ¼ 267) lupus cohorts using commercial Milliplex and ELISA assays. Oxidized LDL/b2glycoprotein antigenic complexes (oxLb2Ag) and their associated antibodies were also measured in the Jamaican cohort. Healthy controls for oxidative marker and cytokine testing were used. Results: Abnormally low vitamin D levels were present in 61.4% and 73.3% of Hopkins and Jamaican SLE patients, respectively. Median concentrations of IP10, TNFa, sCD40L and VEGF were elevated in both cohorts, oxLb2Ag and IL-6 were elevated in the Jamaican cohort, and IFNa, IL-1b and IL-8 were the same or lower in both cohorts compared to controls. IP10 and VEGF were independent predictors of disease activity, aPL, IP10 and IL-6 were independent predictors of thrombosis and IL-8, and low vitamin D were independent predictors of pregnancy morbidity despite there being no association of vitamin D with pro-inflammatory cytokines. Conclusions: Our results indicate that aPL-mediated pro-inflammatory cytokine production is likely a major mechanism of thrombus development in SLE patients. We provide presumptive evidence of the role IL-8 and hypovitaminosis D play in obstetric pathology in SLE but further studies are required to characterize the subtle complexities of vitamin D's relationship with cytokine production and disease activity in these patients. Lupus (2017) 26, 1517-1527.
Introduction
Systemic lupus erythematosus (SLE) is a prototypic systemic autoimmune disease that affects millions of people worldwide and directly targets multiple organ systems resulting in protean clinical manifestations. 1 Antiphospholipid antibodies (aPL), the serological hallmark of antiphospholipid syndrome (APS), are found in approximately 30%-40% of patients with SLE, and approximately 50% of those patients fulfill criteria to be classified as having secondary APS. 2 Abnormal biological activity of cytokines plays an important role in the pathophysiology of both SLE and APS and several studies have highlighted the association of certain pro-inflammatory cytokines with disease activity in SLE. These cytokines include interferon-alpha (IFNa), interferon-inducible protein 10 (IP10), tumor necrosis factora (TNFa), soluble CD40 ligand (sCD40L) and interleukin-6 (IL-6). 3, 4 Tissue factor (TF) and vascular endothelial growth factor (VEGF) have been shown to be upregulated in endothelial cells and monocytes from patients with APS and they appear to be associated with a prothrombotic phenotype observed in these patients. 5 Also, IL-1, IL-6 and IL-8 have been shown to be upregulated by endothelial cells treated with immunoglobulin (Ig)G and IgM aPL antibodies in vitro, 6 and TNFa was shown to be one of the cytokines involved in aPL-mediated pregnancy morbidity in mouse models. 7 Vitamin D primarily plays an important role in bone health and calcium homeostasis but recent evidence has highlighted its potent immunomodulatory properties. Vitamin D may act by suppressing T cell proliferation, monocyte differentiation, dendritic cell proliferation and activation, and major histocompatibility complex class II (MHCII) expression on macrophages. Vitamin D also suppresses production of antibodies and certain proinflammatory cytokines. 8 A high prevalence of vitamin D insufficiency and deficiency has been demonstrated in SLE patients that has been attributed to avoidance of sun exposure, glucocorticoid use and renal disease. [9] [10] [11] An increase in serum vitamin D levels has now been shown to help SLE activity in both a cohort study 12 and a randomized clinical trial. 13 Similarly, vitamin D insufficiency is more prevalent in APS patients compared to normal controls and furthermore, abnormally low vitamin D levels correlate with thrombosis in these patients. 14 However, there are limited data on the association of vitamin D levels with various proinflammatory biomarkers in patients with SLE and APS and their relative clinical impact. As such, we sought to determine the role of serum vitamin D, various aPL as well as proinflammatory cytokines, including IFNa, IP10, TNFa, sCD40L, VEGF, IL-1, IL-8 and IL-6 as markers of disease activity and thrombotic and obstetric clinical outcomes in patients with SLE.
Materials and methods

Characteristics of study population
Serum samples were obtained from 312 patients from two independent SLE cohorts: the Hopkins Lupus Cohort (Johns Hopkins University, Baltimore, MD) ( Patients for whom disease activity measures were available were included in the study if serum samples stored at À20 C were available for testing. The samples used in this study were taken from cohort storage repositories and as such, several samples were previously unfrozen at least once before. Disease activity was measured by the Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score and the physician global assessment score (PGA) in the Hopkins cohort and the British Isles Lupus Assessment Group (BILAG) index score in the Jamaican cohort. Patients eligible for inclusion in the study were classified into three categories based on results of 25-hydroxy-vitamin D (25-OH VD) testing, such that normal vitamin D levels were defined as being above 30 ng/ml, vitamin D insufficiency as levels between 20 and 30 ng/ml and vitamin D deficiency as levels below 20 ng/ml. Patients who at the time of testing were receiving immunosuppressants such as azathioprine, cyclophosphamide, mycophenalate mofetil or prednisone doses above 10 mg daily were excluded as these agents may affect cytokine levels. Similarly, patients who had significant renal disease defined as a glomerular filtration rate of less than 60 ml/min/1.73 m 2 , which may affect vitamin D levels, were also excluded. 15 Serum samples from healthy patients with no evidence of inflammatory disease were included in the study as controls for cytokine testing (n ¼ 30, 83.3% female, mean age 43.5 AE 12.5, range 18-65) and as controls for oxidative biomarker testing (n ¼ 51, 45.1% female, mean age 49.4 AE 11.0, range 26-76). These sera were obtained from healthy individuals evaluated at the Antiphospholipid Standardization Laboratory, University of Texas Medical Branch. The institutional review boards from the respective institutions approved the use of samples and clinical data from all patients. For each patient, the same sample was used in all in vitro assays and all testing was performed at the Antiphospholipid 
Characteristics of aPL test
Anticardiolipin (aCL) antibodies (IgG, IgM and IgA) were evaluated using an in-house enzymelinked immunosorbent assay (ELISA) method as previously described. 16 IgG, IgM and IgA anti-b2 glycoprotein I (anti-b2GPI) antibodies were determined using the commercial QUANTA Lite Õ anti-b2GPI assay (INOVA Diagnostics, San Diego, CA, USA). All assays were performed manually according to the manufacturer's instructions and were considered positive when titers were above their pre-established cut-off points.
Oxidative marker testing
Markers of oxidative stress including IgG anti-oxidized low-density lipoprotein/b2glycoprotein I antibodies (a-oxLb2Ab) and oxidized low-density lipoprotein/b2-glycoprotein I antigen complex (oxLb2Ag) were both measured using commercially available ELISA kits (Corgenix, Broomfield, CO, USA) in serum samples from the Jamaican cohort of patients. Positive IgG a-oxLb2Ab titers were defined by the manufacturer as greater than 19 G units. Serum samples from the control group of healthy individuals were used to determine normal levels of oxLb2Ag, which were defined as the 99th percentile of the concentrations obtained in the control group.
Cytokine testing
The MILLIPLEXMAP human cytokine/chemokine panel assay (Millipore, Billerica, MA), which utilizes Luminex xMAP technology, was used to determine serum levels of the cytokines IL-1b, IL-6, IL-8, TNFa, IFNa, IP10, VEGF and sCD40L as described previously. 17 Briefly, 25 l of patient serum or plasma was incubated with color-coded bead sets, each being specific for one of the analytes being tested. A biotinylated detection antibody was then introduced followed by incubation with streptavidin-phycoerythrin, which acted as the reporter molecule on the surface of each microsphere. To determine the number/percentage of SLE patient samples elevated for each cytokine, we defined a cut-off value as the 99th percentile of the concentrations obtained in the control sera.
Vitamin D testing
Total serum concentrations of 25-OH VD were determined using a commercially available ELISA assay using competitive inhibition of labeled vitamin D standards (Eagle Biosciences, Nashua, NH, USA).
Statistical analysis
Results were expressed as mean AE SD or median with the corresponding interquartile range. Vitamin D levels across seasons and cytokine and oxidative marker levels across cohort and control groups were evaluated using one-way analysis of variance (ANOVA) with Tukey post-hoc analysis or the Kruskal-Wallis test with post-hoc multiple pairwise comparisons using the Steel-Dwass-Critchlow-Fligner procedure as required. Univariate association between continuous variables were performed using Pearson correlation and between dichotomous variables using Pearson chi-squared or Fisher's exact test as appropriate.
For multivariate analysis, a forward stepwise linear regression model and forward stepwise logistic regression model were used for continuous and dichotomous response variables, respectively. The analysis was performed using the xlstat software, version 16.6 (Addinsoft, NY) and results were considered statistically significant if p values were less than 0.05 (p < 0.05). Table 1 summarizes the baseline demographics and prevalence of APS-and SLE-related clinical features of the study population and controls. APSrelated manifestations occurred two to eight times more frequently in the Hopkins cohort compared to the Jamaican SLE cohort. While the difference in the frequency of arterial thrombosis between the two cohorts achieved statistical significance, the other comparisons of APS-related manifestations only approached statistical significance. However, the prevalence of aPL positivity, both at cut-off and at APS classification criteria levels, were similar in both cohorts as was the prevalence of SLE criteria manifestations. Interestingly, the mean duration of disease was over 15 years in the Hopkins cohort, almost three times as that in the Jamaican lupus cohort. Hopkins and Jamaican SLE patients included in the study were treated with hydroxychloroquine (HCQ) and/or low-dose prednisone;
Results
Patient demographics and clinical data
however, HCQ was used more frequently in the Hopkins cohort while prednisone was most commonly used in the Jamaican cohort. The cytokine and oxidative biomarker control patients had no APS-related clinical manifestations and were all aPL negative.
Proinflammatory cytokines and oxidative markers
As shown in Table 2 , median serum concentrations of TNFa, IP10, sCD40L and VEGF were significantly elevated in both SLE cohorts compared to the control population. Interestingly, while median IL-6 levels were higher in the Jamaican SLE cohort compared to controls, there was no statistical difference between IL-6 levels in the Hopkins Lupus cohort and controls. A total of 2/45 (6.5%) SLE patients in the Jamaican cohort were positive for a-oxLb2Ab and both these patients were positive for at least one aPL. Median oxLb2Ag levels were also significantly elevated in the Jamaican cohort compared to controls. Conversely, median levels of IL-1b, IFNa and IL-8 in both cohorts were either significantly less or statistically similar to levels in the control patients.
Vitamin D distribution
The relative frequency of 25-OH VD concentrations in the 267 SLE patients from the Hopkins cohort and the 45 patients from the Jamaican cohort is shown in Figure 1 . <0.0001 Dx duration (mean AE SD) (Range) 5 202.5 AE 128.9 (7-621) 81.6 AE 60.6 (6-288) <0.0001
The prevalence of aPL positivity was considered at assay cut-off 1 or at APS classification criteria levels. 2 These manifestations 3 were identified as present if the parameters of the particular SLE ACR classification criteria were met. All patients that were being treated with prednisone 4 were taking low doses (less than 10 mg daily). Disease (Dx) duration 5 (71/267) classified as vitamin D insufficient. There was no statistically significant difference in vitamin D levels between the two cohorts (p ¼ 0.613).
In order to determine the effect of seasonal variation on vitamin D levels in both cohorts, we assessed the monthly variation in mean 25-OH VD levels. Samples were grouped into four categories based on collection dates: winter (January to March), spring (April to May), summer (June to September) and autumn (October to December). As shown in Figure 2 , the variation of mean 25-OH VD levels by season was not statistically significant. Table 3 shows the correlation of aPL, oxidative markers, pro-inflammatory cytokines and 25-OH VD levels. Unsurprisingly, there was good to Figure 1 Vitamin D levels below 20 ng/ml and levels between 20 ng/ml and 30 ng/ml are defined as vitamin D deficiency and insufficiency, respectively. Abnormal vitamin D levels occurred in more than 60% of patients in the Hopkins cohort and more than 70% of patients in the Jamaican cohort. In both cohorts, the correlation between aPL was generally fair to moderate, the highest values occurring between aPL of the same isotype. In the Jamaican cohort, IgG a-oxLb2Ab had excellent to almost perfect correlation with IgG aCL (r ¼ 0.86, p < 0.0001) and IgG anti-b 2 GPI (r ¼ 0.98, p < 0.0001). In the Hopkins cohort, there was no significant correlation between 25-OH VD levels and any aPL or pro-inflammatory biomarkers. In the Jamaican cohort, however, there was a moderately strong positive association of 25-OH VD with oxLb2Ag (r ¼ 0.50, p ¼ 0.0006) but vitamin D levels were not associated with any pro-inflammatory cytokine.
Biomarker associations
Disease activity
In the Hopkins cohort, SELENA-SLEDAI and PGA were used as measures of disease activity, and correlation with proinflammatory biomarkers is shown in Table 3 . The mean SELENA-SLEDAI score was 2.2 AE 3.2 (range 0-25.2) and a total of 27/ 267 (10.1%) patients had a clinically significant score (!6.0). Unsurprisingly, the SELENA-SLEDAI score had a moderately strong association with the PGA (r ¼ 0.63, p < 0.0001). The SELENA-SLEDAI score was also significantly associated, albeit relatively weakly, with the cytokines IP10 (0.32, p < 0.0001), IFNa (r ¼ 0.24, p < 0.0001) and VEGF (r ¼ 0.33, p < 0.0001) as well as IgA antib 2 GPI (r ¼ 0.13, p ¼ 0.034). The PGA itself was significantly associated with IP10 (r ¼ 0.18, p < 0.001) and VEGF (r ¼ 0.18, p < 0.001) levels as well.
In multivariate linear regression analysis only the association of SELENA-SLEDAI with VEGF (p < 0.0001) and IP10 (p < 0.0001) remained statistically significant, with a total R 2 of 0.171 indicating a relatively weak relationship.
In the Jamaican lupus cohort, the BILAG index was the instrument used to measure disease activity and correlations are also shown in Table 3 . The mean BILAG index score was 2.7 AE 1.9 (range 1-9) and a total of 13/46 (28.2%) had moderate disease activity level (grade B) in at least one organ system; none had severe activity (grade A). The only significant association with the BILAG index occurred with the cytokine IP10 (r ¼ 0.36, p ¼ 0.016), which maintained significance in multivariate linear regression analysis (R 2 ¼ 0.13, p ¼ 0.016) ( Table 3 ).
Thrombosis
The univariate association of the various proinflammatory biomarkers with APS-related clinical were also associated with venous thrombosis (Table 4) ; however, these did not remain statistically significant in multivariate logistic regression analysis. Arterial thrombosis in the Hopkins cohort was significantly associated with anti-b2GPI IgA (OR 2.2 95% CI 1.0-5.0, p ¼ 0.050), IL-6 (OR 3.0 95% CI 1.6-5.7, p ¼ 0.0005), TNFa (OR 2.5 95% CI 1.3-4.6, p ¼ 0.004), IP10 (OR 3.1 95% CI 1.4-6.7), p ¼ 0.005) and IL-8 (OR 9.3 95% CI 1.9-45.3, p ¼ 0.002). In multivariate analysis, the association with IL-6 (OR 2.2 95% CI 1.1-4.3, p ¼ 0.027) and IP10 (OR 2.4 95% CI 1.1-5.6, p ¼ 0.039) remained significant. In the Jamaican cohort, aCL IgG was positively associated with arterial thrombosis (OR 13.3, 95% CI 1.1-164.5), while oxLb2Ag was negatively associated (OR 0.1 95% CI 0.0-0.7, p ¼ 0.020). Both aCL IgG (OR 95.7, 95% CI 1.5-626.5, p ¼ 0.033) and oxLb2Ag (OR 0.04, 95% CI 0.01-1.00, p ¼ 0.050) remained significant in multivariate logistic regression analysis.
Pregnancy morbidity
In the Hopkins cohort, pre-eclampsia/eclampsia (PE/E) was significantly associated with low 25-OH VD levels (OR 4.4 95% CI 1.4-14.1, p ¼ 0.012), sCD40L (OR 19.6, 95% CI 2.7-140.7, p ¼ 0.003) and IL-8 (OR 5.4 95% CI 1.1-26.8, p ¼ 0.037). Abnormal vitamin D levels (OR 3.9 95% CI 1.3-11.8, p ¼ 0.016) and IL-8 (OR 24.4 95% CI 1.9-317.3, p ¼ 0.015) remained significantly associated with PE/E in multivariate analyses. However, there were no significant associations of the various markers with miscarriage in the Hopkins cohort or with miscarriage or PE/E in the Jamaican cohort.
Discussion
In this study, we evaluate the impact of vitamin D, proinflammatory cytokines and aPL on clinical outcomes in two independent SLE cohorts. The distribution of 25-OH VD levels in the Hopkins and Jamaican cohorts were strikingly similar, with mean levels in each cohort falling below what is considered the normal reference value of 30 ng/ ml. 18 The observed high prevalence of vitamin D deficiency and insufficiency in these cohorts has been shown in previous studies of both cohorts 12, 19 as well as in other independent studies. It is a common finding that transcends differences in ethnicity 20 and has largely been thought to occur as a result of disease activity limiting nutritional intake and sunlight exposure. It is now widely accepted, however, that the low vitamin D levels seen in SLE patients may also contribute to the pathogenesis of disease, through the resultant decrease in its immunomodulatory effect, rather than occurring as an epiphenomenon. 20 We confirm the presence of several pro-inflammatory cytokines including IP10, IL-6, VEGF, TNFa and sCD40L in elevated concentrations in SLE patients compared to healthy controls. These findings were largely consistent in both cohorts and are in keeping with previous studies. [21] [22] [23] The cytokines IP10, sCD40L and TNFa are important mediators of B and T lymphocyte activation, inflammation and autoantibody production in SLE and the consistent elevation of these cytokines is likely a reflection of the central importance of these immune processes in SLE pathogenesis. 24 Similarly, VEGF is of paramount importance in the development of vascular pathology in SLE patients and is a useful biomarker for detecting systemic involvement in these patients. 5 Most previous clinical studies have also failed to demonstrate elevations of IL-1b and IL-8 levels in SLE patients compared to controls, although studies in mice have highlighted the importance of IL-1b in the pathogenesis of experimental SLE. 25 The higher level of IFNa in our SLE cohorts compared to controls was not statistically significant and this was somewhat surprising given the central importance of this cytokine and, more generally, the IFN-gene signature in SLE and APS pathogenesis. 21, 26 The reason for this paradoxical finding is unclear but could possibly be due to differences in the levels of IFNa in clinical subgroups of SLE patients. Despite this, however, the IFNdriven cytokine IP10 in the Jamaican cohort and IFNa, IP10, VEGF and IgA anti-b 2 GPI in the Hopkins cohort were all associated with disease activity, with the major contributors being IP10 and VEGF. This further underscores the importance of IFN-induced cytokine activity and vascular pathology in driving disease activity in SLE patients. Table 4 Univariate association of pro-inflammatory cytokines, oxidative markers, antiphospholipid antibodies and vitamin D with APS-related clinical manifestations expressed as odds ratios with 95% confidence intervals Unsurprisingly, several aPL were associated with venous and arterial thrombosis in both cohorts, and a commonly accepted theory for thrombus development in aPL-positive patients is the induction of a pro-inflammatory phenotype via cytokines and chemokines decreasing the threshold for thrombosis. 5, 6 Indeed, the association of pro-inflammatory IP10, IL-8 and VEGF with venous thrombosis and IP10, IL-8, IL-6 and TNFa with arterial thrombosis indicate that this ''two-hit'' hypothesis is likely a major mechanism of thrombus development in our SLE patients. Quite a surprising finding was the seemingly reduced risk of arterial thrombosis associated with elevated oxLb2Ag levels. Previous studies have shown that high serum levels of oxLb2Ag complexes are common in SLE patients and they may act as atherogenic autoantigens increasing the risk of autoimmune-mediated thrombosis and atherosclerosis. 27 We are unsure how to explain this discrepancy; however, the protective role of these complexes as well as the moderately strong positive association with vitamin D in our patients hint at a more complex association between these oxidative biomarkers and autoimmune-mediated thrombosis in SLE than previously indicated. This is especially true given the inconclusive reports of the effect of vitamin D levels on the risk of thrombosis in APS and SLE patients. 14 Indeed, supplementation of calcium with or without vitamin D has even been shown to modestly increase the risk of cardiovascular events, especially myocardial infarction in a recent meta-analysis. 28 Low vitamin D levels and IL-8 were independently associated with PE/E in our study population. Previous studies have reported higher levels of serum IL-8 in women with PE and intrauterine growth retardation compared to women with normal pregnancies. Serum IL-8 levels were also higher in those with severe versus mild PE. 29 Although we saw no correlation of aPL with pregnancy morbidity in our patients, recent in vitro studies have shown that aPL can induce IL-8 and IL-6 secretion in trophoblasts. 30 Vitamin D treatment alone or in combination with low molecular weight heparin has also been shown to attenuate the aPL-mediated proinflammatory response in trophoblast cultures. 31 It should be noted, however, that while currently available clinical evidence indicates no association between hypovitaminosis D and obstetric APS manifestations, a recent crosssectional study of women with recurrent pregnancy loss reported an association between low vitamin D levels and increased odds of positive aPL. 32 Previous studies in both the Hopkins Lupus Cohort and in a clinical trial have proven that an increase in vitamin D helps global lupus activity. 12, 13 Our findings support those of a recently published study that reported no association between vitamin D levels and the cytokines IFNa, IFNg, IL2, TNF, IL-10, IL-6, IL4, IL-17, IL21, IL-12p70 and IL23. 33 In addition to IFNa, TNFa and IL-6, we show that vitamin D levels are not associated with IL-1b, IP10, sCD40L, IL-8 or VEGF in either SLE cohort. Based on our results and previous data, the beneficial effect of vitamin D in SLE seems to occur independently of any changes in proinflammatory cytokines. Indeed, vitamin D supplementation was shown to significantly improve disease activity and the urine protein-to-creatinine ratio in the Hopkins cohort patients without a marked change in serological markers.
In the present study, the lack of controlled vitamin D supplementation, the use of previously unfrozen samples that may affect cytokine levels, the cross-sectional nature of the study and the relatively small number of patients as a result of strict inclusion criteria are recognized limitations. However, we show that there was no significant seasonal variation in vitamin D levels and we believe that limiting the extraneous factors that may have affected cytokine and vitamin D levels as well as the high correlation between acutephase reactant cytokines increases the validity of our results. Similarly, the consistency of a majority of our findings in two independent SLE cohorts also suggests that our findings are representative and perhaps some of the noted differences could be explained by a difference in duration of disease in the two cohorts. Our results indicate that aPLmediated pro-inflammatory cytokine production is likely a major mechanism of thrombus development in SLE patients, and we provide presumptive evidence of the role IL-8 and hypovitaminosis D play in obstetric pathology in SLE. The molecular mechanisms responsible for the potentially beneficial effects of vitamin D in SLE patients are very likely complex in nature and are probably dependent on several genetic and environmental factors yet to be determined. Further longitudinal studies using larger groups of SLE patients of varying ethnicities and clinical phenotypes are necessary to fully characterize these subtle complexities.
